Evidence map›Paper›PMID 41841205›Full record

ArticleActa crystallographica. Section F, Structural biology communications2026

Crystallization and 1.6 Å resolution crystal structure of an acylated GLP-1/GIP analogue peptide.

Hamish M Mitchell, Boguslaw Nocek, Emily J Guinn, Jerry Y Y Heng

Abstract read
In one paragraph

Article in Acta crystallographica. Section F, Structural biology communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Hamish M MitchellDepartment of Chemical Engineering, Imperial College London, London SW7 2AZ, United Kingdom.ORCID 0000-0001-6715-0116
Boguslaw NocekDiscovery Chemistry Research and Technology, Lilly Corporate Center, Eli Lilly and Company, Indianapolis, IN 46285, USA.ORCID 0000-0001-8257-0792
Emily J GuinnSynthetic Molecule Design and Development, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46221, USA.ORCID 0000-0002-9974-3458
Jerry Y Y HengDepartment of Chemical Engineering, Imperial College London, London SW7 2AZ, United Kingdom.ORCID 0000-0003-2659-5500

Funding

Engineering and Physical Sciences Research Council EP/T005556/1Engineering and Physical Sciences Research Council EP/T518207/1
6 · The paper itself

Abstract

With the meteoric rise in interest in GLP-1 and GIP analogue peptides in recent years, there is a drive for the use of alternative purification techniques to alleviate processing bottlenecks and reduce the cost of peptide manufacturing. However, a lack of reported crystal structures for this class of peptides has hindered molecular-scale understanding of GLP-1/GIP analogue peptide crystallization, particularly related to acylated peptides. This paper therefore reports what is believed to be the first crystal structure of a GLP-1 and GIP analogue lipopeptide. Crystals obtained using a microseed matrix-screening protocol diffracted to ≤1.6 Å resolution in space group P4

Indexed as

Gastric Inhibitory PolypeptideGlucagon-Like Peptide 1AcylationAmino Acid SequenceCrystallizationCrystallography, X-RayModels, MolecularGastric Inhibitory PolypeptideGlucagon-Like Peptide 1crystallizationdiabetesGLP-1obesitypeptides

Identifiers

PMID41841205
PMCPMC13041627

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.